Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Road rash

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: Road rash. Displaying page 2 of 2.
    « Previous 1  2 
    EudraCT Number: 2019-000638-20 Sponsor Protocol Number: M19-130 Start Date*: 2020-01-22
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic ...
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) NL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003169-15 Sponsor Protocol Number: P04273 Start Date*: 2006-12-14
    Sponsor Name:Schering Plough Research Institute
    Full Title: A Phase 2 study of temozolomide (SCH 52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-guanine-DNA Methyltransferase (MGMT) Promoter
    Medical condition: Advanced Aerodigestive Tract Cancers (Colorectal Cancer (CRC), Non Small Cell Lung Cancer (NSCLC), Head and Neck (H&N), Esophageal Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028980 Neoplasm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) PT (Prematurely Ended) SE (Prematurely Ended) GR (Completed) NL (Prematurely Ended) IT (Completed) GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-005060-18 Sponsor Protocol Number: 2016AL002 Start Date*: 2018-03-09
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: The Role of Uric Acid Metabolism in Pathogenesis of Anaphylaxis: the Effect of Allopurinol on Experimentally-induced Allergic Reaction to Peanut in Peanut Allergic Adults- a randomised, double-blin...
    Medical condition: Determination of the Lowest Observed Adverse Event level dose (LOAEL)of peanut in individual suffering with peanut allergy, after treatment with allopurinol.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10001738 Allergy LLT
    20.0 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-019820-30 Sponsor Protocol Number: CC-4047-MM-003 Start Date*: 2011-03-31
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination with Low-Dose Dexamethasone versus High-Dose Dexamethasone in Subjects with Re...
    Medical condition: Refractory Multiple Myeloma (MM) or relapsed and refractory MM.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) GR (Completed) IT (Completed) CZ (Completed) NL (Completed) ES (Completed) SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-015957-20 Sponsor Protocol Number: ARTEMIS Start Date*: 2010-02-16
    Sponsor Name:Karolinska University Hospital
    Full Title: Abatacept treatment in polymyositis and dermatomyositis
    Medical condition: polymyositis and dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036102 Polymyositis LLT
    12.1 10012503 Dermatomyositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) CZ (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003490-26 Sponsor Protocol Number: WA28118 Start Date*: 2013-08-08
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH SYSTEMIC JUVENILE I...
    Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002678-19 Sponsor Protocol Number: SP148MP201 Start Date*: 2018-03-20
    Sponsor Name:SmartPractice
    Full Title: Clinical Evaluation of Metal Panel Allergens: Aluminum, Copper, Manganese, Molybdenum, Tin, Titanium, Vanadium and Zinc Dose Response Study
    Medical condition: Metal induced contact dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000435-33 Sponsor Protocol Number: NP25737 Start Date*: 2015-08-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase I pharmacokinetic and safety study of tocilizumab (TCZ) in patients less than 2 years old with active systemic juvenile idiopathic arthritis (sJIA)
    Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BE (Completed) ES (Completed) PL (Completed) GB (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-023802-10 Sponsor Protocol Number: B1801023 Start Date*: 2011-07-29
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017
    Full Title: AN OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG TERM SAFETY OF ETANERCEPT IN CHILDREN AND ADOLESCENTS WITH EXTENDED OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS RELATED ARTHRITIS, OR P...
    Medical condition: OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS RELATED ARTHRITIS, OR PSORIATIC ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) FR (Completed) LT (Completed) SK (Completed) CZ (Completed) SI (Completed) ES (Completed) DE (Completed) LV (Completed) PL (Completed) NL (Completed) Outside EU/EEA NO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005281-30 Sponsor Protocol Number: DUR001-306 Start Date*: 2016-11-03
    Sponsor Name:Allergan Ltd.
    Full Title: A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Sk...
    Medical condition: Acute bacterial skin and skin structure infection. For Cohort 5 (from birth to less than 3 months) also patients with sepsis are allowed.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10066412 Staphylococcus aureus skin infection LLT
    20.0 10021881 - Infections and infestations 10037633 Pyoderma (skin infection) LLT
    20.1 10021881 - Infections and infestations 10040873 Skin infection aggravated LLT
    20.0 10021881 - Infections and infestations 10040872 Skin infection PT
    20.0 10021881 - Infections and infestations 10040875 Skin infection pyogenic LLT
    20.0 10021881 - Infections and infestations 10040874 Skin infection NOS LLT
    20.1 10021881 - Infections and infestations 10066409 Staphylococcal skin infection PT
    20.0 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) BG (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020150-34 Sponsor Protocol Number: V212-001-01 Start Date*: 2010-10-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet...
    Medical condition: Incidence of Herpes Zoster in recipients of Autologous HCTs
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed) SE (Completed) CZ (Completed) GB (Completed) LT (Completed) IT (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023156-89 Sponsor Protocol Number: V212-011 Start Date*: 2011-02-24
    Sponsor Name:Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc
    Full Title: Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica. A Phase III Rando...
    Medical condition: Incidence of Herpes Zoster in adults with solid tumor or hematologic malignancy Incidencia de Herpes Zoster en pacientes adultos con tumor sólido o neoplasia hematológica.
    Disease: Version SOC Term Classification Code Term Level
    13 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) CZ (Completed) GB (Completed) SK (Completed) AT (Completed) BE (Completed) EE (Completed) LT (Completed) GR (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019318-26 Sponsor Protocol Number: IMCL_CP12-0919_(I4T-IE-JVBF) Start Date*: 2010-09-27
    Sponsor Name:ImClone LLC
    Full Title: A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepato...
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) CZ (Completed) PT (Completed) BE (Completed) ES (Completed) AT (Completed) FR (Completed) BG (Completed) HU (Completed) IT (Completed) SE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2008-000252-28 Sponsor Protocol Number: SHCVOLT1 Start Date*: 2009-03-13
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A Multi-Centre Prospective Controlled Trial Comparing Calcineurin Inhibitor Monotherapy With Sirolimus Monotherapy in Hepatitis C Infected Patients with Hepatic Fibrosis Following Liver Transplanta...
    Medical condition: Patients who have undergone liver transplantation and are infected with Hepatitis C virus.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052779 Transplant rejections HLT
    9.1 10024970 Respiratory tract infections HLGT
    9.1 10046577 Urinary tract infections HLT
    9.1 10001032 Acute pyelonephritis LLT
    9.1 10040072 Septicaemia LLT
    9.1 10019972 Herpes viral infections HLT
    9.1 10028440 Mycobacterial infectious disorders HLGT
    9.1 10015107 Epstein-Barr viral infections HLT
    9.1 10011831 Cytomegalovirus infection LLT
    9.1 10019974 Herpes zoster LLT
    9.1 10058872 Fungal sepsis LLT
    9.1 10040808 Skin cancer PT
    9.1 10051358 Post transplant lymphoproliferative disorder LLT
    9.1 10043555 Thrombocytopenias HLT
    9.1 10037561 Purpura thrombocytopenic LLT
    9.1 10002034 Anaemia PT
    9.1 10018932 Haemolytic uraemic syndrome PT
    9.1 10024384 Leukopenia PT
    9.1 10029355 Neutropenias HLT
    9.1 10033661 Pancytopenia PT
    9.1 10013505 Disturbance of liver function tests LLT
    9.1 10002218 Anaphylaxis LLT
    9.1 10002425 Angioedemas HLT
    9.1 10015665 Exfoliative dermatitis LLT
    9.1 10020764 Hypersensitivity vasculitis LLT
    9.1 10021015 Hypokalaemia PT
    9.1 10021058 Hypophosphataemia PT
    9.1 10020603 Hypercholesterolaemia PT
    9.1 10020635 Hyperglycaemia PT
    9.1 10020869 Hypertriglyceridaemia PT
    9.1 10043071 Tachycardia PT
    9.1 10034474 Pericardial effusion PT
    9.1 10048642 Lymphocele PT
    9.1 10051055 Deep vein thrombosis PT
    9.1 10037377 Pulmonary embolism PT
    9.1 10025282 Lymphoedema PT
    9.1 10035742 Pneumonitis PT
    9.1 10035598 Pleural effusion PT
    9.1 10015090 Epistaxis PT
    9.1 10037394 Pulmonary haemorrhage PT
    9.1 10000081 Abdominal pain PT
    9.1 10012735 Diarrhoea PT
    9.1 10042128 Stomatitis PT
    9.1 10033645 Pancreatitis PT
    9.1 10000496 Acne PT
    9.1 10037844 Rash PT
    9.1 10003239 Arthralgia PT
    9.1 10031264 Osteonecrosis PT
    9.1 10037032 Proteinuria PT
    9.1 10029164 Nephrotic syndrome PT
    9.1 10030124 Oedema peripheral PT
    9.1 10021519 Impaired healing PT
    9.1 10030095 Oedema PT
    9.1 10037660 Pyrexia PT
    9.1 10005630 Blood lactate dehydrogenase increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 14:03:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA